$28.91
0.130.45%
At Close: -
$28.91
00.00%
After Hours: 4:00 PM EDT
15 minutes delayed
Comments
Loading...
Arrowhead Pharma
ARWRNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Arrowhead Pharma (NASDAQ:ARWR) Stock, Analyst Ratings, Price Targets, Forecasts
Arrowhead Pharmaceuticals Inc has a consensus price target of $49.29 based on the ratings of 19 analysts. The high is $80 issued by SMBC Nikko on April 26, 2023. The low is $27 issued by Morgan Stanley on May 13, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Chardan Capital, and HC Wainwright & Co. on July 23, 2024, July 17, 2024, and July 5, 2024, respectively. With an average price target of $60 between HC Wainwright & Co., Chardan Capital, and HC Wainwright & Co., there's an implied 107.54% upside for Arrowhead Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Chardan Capital
Goldman Sachs
Morgan Stanley
Citigroup
1calculated from analyst ratings
Analyst Ratings for Arrowhead Pharma
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/23/2024 | Buy Now | 107.54% | HC Wainwright & Co. | Patrick Trucchio | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 07/17/2024 | Buy Now | 107.54% | Chardan Capital | Keay Nakae | $60 → $60 | Maintains | Buy | Get Alert |
| 07/05/2024 | Buy Now | 107.54% | HC Wainwright & Co. | Patrick Trucchio | $90 → $60 | Maintains | Buy | Get Alert |
| 06/26/2024 | Buy Now | 107.54% | Chardan Capital | Keay Nakae | $60 → $60 | Maintains | Buy | Get Alert |
| 06/20/2024 | Buy Now | — | Cantor Fitzgerald | Alethia Young | — | Reiterates | → Overweight | Get Alert |
| 06/11/2024 | Buy Now | 211.31% | HC Wainwright & Co. | Patrick Trucchio | $90 → $90 | Reiterates | Buy → Buy | Get Alert |
| 06/05/2024 | Buy Now | 7.23% | Goldman Sachs | Andrea Tan | → $31 | Initiates | → Neutral | Get Alert |
| 06/03/2024 | Buy Now | 211.31% | HC Wainwright & Co. | Patrick Trucchio | $90 → $90 | Reiterates | Buy → Buy | Get Alert |
| 06/03/2024 | Buy Now | 107.54% | Chardan Capital | Keay Nakae | $60 → $60 | Maintains | Buy | Get Alert |
| 05/13/2024 | Buy Now | 211.31% | HC Wainwright & Co. | Patrick Trucchio | → $90 | Reiterates | Buy → Buy | Get Alert |
| 05/13/2024 | Buy Now | -6.61% | Morgan Stanley | Michael Ulz | $36 → $27 | Maintains | Equal-Weight | Get Alert |
| 05/10/2024 | Buy Now | 107.54% | Chardan Capital | Keay Nakae | $60 → $60 | Maintains | Buy | Get Alert |
| 02/08/2024 | Buy Now | 211.31% | HC Wainwright & Co. | Patrick Trucchio | → $90 | Reiterates | Buy → Buy | Get Alert |
| 02/07/2024 | Buy Now | 24.52% | Morgan Stanley | Michael Ulz | $34 → $36 | Maintains | Equal-Weight | Get Alert |
| 02/07/2024 | Buy Now | 17.61% | Citigroup | Shawn Egan | $33 → $34 | Maintains | Neutral | Get Alert |
| 02/07/2024 | Buy Now | 72.95% | RBC Capital | Luca Issi | → $50 | Reiterates | Outperform → Outperform | Get Alert |
| 01/16/2024 | Buy Now | 72.95% | RBC Capital | Luca Issi | → $50 | Reiterates | Outperform → Outperform | Get Alert |
| 01/02/2024 | Buy Now | 27.98% | B of A Securities | Jason Gerberry | $29 → $37 | Maintains | Buy | Get Alert |
| 12/04/2023 | Buy Now | 0.31% | B of A Securities | Jason Gerberry | → $29 | Initiates | → Buy | Get Alert |
| 11/30/2023 | Buy Now | 27.98% | Morgan Stanley | Michael Ulz | $40 → $37 | Maintains | Equal-Weight | Get Alert |
| 11/30/2023 | Buy Now | 72.95% | RBC Capital | Luca Issi | → $50 | Reiterates | Outperform → Outperform | Get Alert |
| 09/19/2023 | Buy Now | 14.15% | Citigroup | Shawn Egan | → $33 | Initiates | → Neutral | Get Alert |
| 08/09/2023 | Buy Now | 211.31% | HC Wainwright & Co. | Patrick Trucchio | → $90 | Reiterates | Buy → Buy | Get Alert |
| 08/08/2023 | Buy Now | 107.54% | Chardan Capital | Keay Nakae | → $60 | Reiterates | Buy → Buy | Get Alert |
| 08/08/2023 | Buy Now | 62.57% | Cantor Fitzgerald | Alethia Young | $79 → $47 | Maintains | Overweight | Get Alert |
| 08/08/2023 | Buy Now | 107.54% | RBC Capital | Luca Issi | → $60 | Reiterates | Outperform → Outperform | Get Alert |
| 07/21/2023 | Buy Now | — | TD Cowen | Brendan Smith | — | Initiates | → Outperform | Get Alert |
| 07/20/2023 | Buy Now | 90.25% | B. Riley Securities | Mayank Mamtani | → $55 | Reiterates | Buy → Buy | Get Alert |
| 06/30/2023 | Buy Now | 211.31% | HC Wainwright & Co. | Patrick Trucchio | → $90 | Reiterates | Buy → Buy | Get Alert |
| 06/06/2023 | Buy Now | 211.31% | HC Wainwright & Co. | Patrick Trucchio | → $90 | Reiterates | Buy → Buy | Get Alert |
| 06/02/2023 | Buy Now | 104.08% | Piper Sandler | Edward Tenthoff | $52 → $59 | Maintains | Overweight | Get Alert |
| 06/02/2023 | Buy Now | 107.54% | Chardan Capital | Keay Nakae | → $60 | Reiterates | Buy → Buy | Get Alert |
| 05/24/2023 | Buy Now | 107.54% | Chardan Capital | Keay Nakae | → $60 | Reiterates | Buy → Buy | Get Alert |
| 05/12/2023 | Buy Now | 38.36% | SVB Leerink | Mani Foroohar | → $40 | Downgrade | Outperform → Market Perform | Get Alert |
| 05/03/2023 | Buy Now | 107.54% | RBC Capital | Luca Issi | → $60 | Reiterates | → Outperform | Get Alert |
| 05/03/2023 | Buy Now | 152.51% | Goldman Sachs | Madhu Kumar | $65 → $73 | Maintains | Buy | Get Alert |
| 05/03/2023 | Buy Now | 38.36% | Morgan Stanley | Michael Ulz | $37 → $40 | Maintains | Equal-Weight | Get Alert |
| 04/26/2023 | Buy Now | 176.72% | SMBC Nikko | David Hoang | → $80 | Initiates | → Outperform | Get Alert |
| 04/12/2023 | Buy Now | 21.07% | SVB Securities | Mani Foroohar | $21 → $35 | Upgrade | Market Perform → Outperform | Get Alert |
| 03/21/2023 | Buy Now | -6.61% | Bernstein | William Pickering | → $27 | Initiates | → Market Perform | Get Alert |
| 02/10/2023 | Buy Now | 211.31% | HC Wainwright & Co. | Patrick Trucchio | → $90 | Reiterates | → Buy | Get Alert |
| 02/10/2023 | Buy Now | 107.54% | Chardan Capital | Keay Nakae | → $60 | Reiterates | → Buy | Get Alert |
| 02/08/2023 | Buy Now | 90.25% | B. Riley Securities | Mayank Mamtani | $59 → $55 | Maintains | Buy | Get Alert |
| 02/07/2023 | Buy Now | 166.34% | RBC Capital | Luca Issi | $83 → $77 | Maintains | Outperform | Get Alert |
| 02/07/2023 | Buy Now | 100.62% | Baird | Joel Beatty | $60 → $58 | Maintains | Outperform | Get Alert |
| 02/07/2023 | Buy Now | 79.87% | Piper Sandler | Edward Tenthoff | $55 → $52 | Maintains | Overweight | Get Alert |
| 12/06/2022 | Buy Now | 211.31% | HC Wainwright & Co. | Patrick Trucchio | $110 → $90 | Maintains | Buy | Get Alert |
| 11/30/2022 | Buy Now | 104.08% | B. Riley Securities | Mayank Mamtani | $65 → $59 | Maintains | Buy | Get Alert |
| 11/29/2022 | Buy Now | 159.43% | Jefferies | Maury Raycroft | $92 → $75 | Maintains | Buy | Get Alert |
| 11/29/2022 | Buy Now | 27.98% | Morgan Stanley | Andrew Galler | $41 → $37 | Maintains | Equal-Weight | Get Alert |
| 11/29/2022 | Buy Now | 7.23% | SVB Leerink | Mani Foroohar | $33 → $31 | Maintains | Market Perform | Get Alert |
| 11/10/2022 | Buy Now | 121.38% | Piper Sandler | Edward Tenthoff | $72 → $64 | Maintains | Overweight | Get Alert |
| 11/10/2022 | Buy Now | 14.15% | SVB Leerink | Mani Foroohar | $32 → $33 | Maintains | Market Perform | Get Alert |
| 09/09/2022 | Buy Now | 41.82% | Morgan Stanley | Andrew Galler | → $41 | Initiates | → Equal-Weight | Get Alert |
| 08/08/2022 | Buy Now | 124.84% | Goldman Sachs | Madhu Kumar | $58 → $65 | Maintains | Buy | Get Alert |
| 06/03/2022 | Buy Now | 280.49% | HC Wainwright & Co. | Patrick Trucchio | $100 → $110 | Maintains | Buy | Get Alert |
| 05/24/2022 | Buy Now | 128.29% | Goldman Sachs | Madhu Kumar | $90 → $66 | Maintains | Buy | Get Alert |
| 05/11/2022 | Buy Now | 176.72% | Chardan Capital | Keay Nakae | $94 → $80 | Maintains | Buy | Get Alert |
| 05/11/2022 | Buy Now | 149.05% | Piper Sandler | Edward Tenthoff | $89 → $72 | Maintains | Overweight | Get Alert |
| 05/11/2022 | Buy Now | 107.54% | Baird | Joel Beatty | $71 → $60 | Upgrade | Neutral → Outperform | Get Alert |
| 05/11/2022 | Buy Now | 21.07% | SVB Leerink | Mani Foroohar | $36 → $35 | Maintains | Market Perform | Get Alert |
| 02/03/2022 | Buy Now | 24.52% | SVB Leerink | Mani Foroohar | $46 → $36 | Maintains | Market Perform | Get Alert |
| 01/28/2022 | Buy Now | 59.11% | SVB Leerink | Mani Foroohar | $45 → $46 | Maintains | Market Perform | Get Alert |
| 01/19/2022 | Buy Now | — | Goldman Sachs | Madhu Kumar | — | Upgrade | Neutral → Buy | Get Alert |
| 11/23/2021 | Buy Now | 55.66% | SVB Leerink | Mani Foroohar | — | Maintains | Market Perform | Get Alert |
| 08/10/2021 | Buy Now | 245.9% | HC Wainwright & Co. | Patrick Trucchio | — | Maintains | Buy | Get Alert |
| 08/06/2021 | Buy Now | 225.15% | Chardan Capital | Keay Nakae | — | Maintains | Buy | Get Alert |
FAQ
What is the target price for Arrowhead Pharma (ARWR) stock?
The latest price target for Arrowhead Pharma (NASDAQ:ARWR) was reported by HC Wainwright & Co. on July 23, 2024. The analyst firm set a price target for $60.00 expecting ARWR to rise to within 12 months (a possible 107.54% upside). 26 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Arrowhead Pharma (ARWR)?
The latest analyst rating for Arrowhead Pharma (NASDAQ:ARWR) was provided by HC Wainwright & Co., and Arrowhead Pharma reiterated their buy rating.
When was the last upgrade for Arrowhead Pharma (ARWR)?
The last upgrade for Arrowhead Pharmaceuticals Inc happened on April 12, 2023 when SVB Securities raised their price target to $35. SVB Securities previously had a market perform for Arrowhead Pharmaceuticals Inc.
When was the last downgrade for Arrowhead Pharma (ARWR)?
The last downgrade for Arrowhead Pharmaceuticals Inc happened on May 12, 2023 when SVB Leerink changed their price target from N/A to $40 for Arrowhead Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Arrowhead Pharma (ARWR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Arrowhead Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Arrowhead Pharma was filed on July 23, 2024 so you should expect the next rating to be made available sometime around July 23, 2025.
Is the Analyst Rating Arrowhead Pharma (ARWR) correct?
While ratings are subjective and will change, the latest Arrowhead Pharma (ARWR) rating was a reiterated with a price target of $60.00 to $60.00. The current price Arrowhead Pharma (ARWR) is trading at is $28.91, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.